Federal COVID Response Team Speaks to ACCP Members About Monoclonal Antibody Treatments

Published on: Aug 11, 2021

The Federal COVID Response (FCR) Therapeutics Team, under the U.S. Department of Health and Human Services, provides resources to support rapid access to monoclonal antibody (mAb) treatment for high-risk COVID-19 patients. Early intervention with monoclonal antibody treatment may reduce the risk of severe illness and hospitalization for people with COVID-19 who are at high risk for developing more serious illness. As therapeutic benefit relies on early identification and initiation of treatment, the FCR team seeks to engage clinical pharmacists in mitigating disease severity by helping to identify patients who may benefit and start them on treatment in a timely process, particularly with surges anticipated in coming weeks and months.

On July 22, ACCP hosted a discussion with representatives from the FCR Team and the HHS Office of the Assistant Secretary for Preparedness & Response, providing an opportunity for ACCP members to ask questions about monoclonal antibody treatments ranging from clinical and operational considerations to equitable access. Stream the recording of this 30-minute session below. Slides are available here.

For additional resources on monoclonal antibody treatments, visit the CombatCOVID website.